Nutriband Develops Innovative Abuse-Deterrent Transdermal Drug Technology
Nutriband Inc. is advancing pharmaceutical safety through its AVERSA technology, which aims to prevent drug abuse and misuse in transdermal patches while maintaining patient access to critical medications.
Nutriband Inc. is pioneering a novel approach to pharmaceutical safety with its AVERSA transdermal drug technology, focusing on developing abuse-deterrent patches for high-risk medications. The company's innovative platform targets improving drug safety across multiple pharmaceutical applications, particularly for medications with potential for misuse.
The AVERSA technology represents a significant advancement in pharmaceutical development, with an expansive international patent portfolio covering key markets including the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. This broad intellectual property protection underscores the technology's potential global impact on medication safety.
Nutriband's strategic business model centers on applying its transdermal technology to existing FDA-approved drugs. By doing so, the company aims to enhance medication safety, improve patient comfort, and leverage a regulatory pathway that potentially reduces clinical trial requirements for new drug approvals.
The company's lead product is an abuse-deterrent fentanyl patch that incorporates AVERSA technology. This approach directly addresses critical public health concerns surrounding opioid medication misuse, offering a potential solution to prevent drug abuse, unauthorized diversion, and accidental exposure.
With its innovative approach, Nutriband is positioning itself at the forefront of pharmaceutical safety innovations, potentially transforming how high-risk medications are developed and administered to minimize potential abuse while maintaining patient access to necessary treatments.